Literature DB >> 1538510

Prospective clinical study with in vitro endothelial cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction.

H Magometschnigg1, M Kadletz, M Vodrazka, W Dock, M Grimm, M Grabenwöger, E Minar, M Staudacher, G Fenzl, E Wolner.   

Abstract

A nonrandomized prospective clinical study was undertaken to evaluate the technique and efficacy of in vitro endothelial cell lining of synthetic grafts. Twenty-six patients (10 men and 16 women with a mean age of 68.4 years; range, 49 to 80 years) with end stage chronic peripheral vascular disease requiring reoperation were entered into the study. In 13 patients venous endothelial cells were harvested 4 to 7 weeks before operation, grown to confluency in culture flasks, and seeded onto the inner surface of expanded polytetrafluoroethylene grafts. Thirteen patients received untreated expanded polytetrafluoroethylene grafts and served as a control. A scoring system with use of intraarterial angiography was used to assess disease severity. No statistically significant differences in angiographic score were seen between the two groups, indicating comparable severity of disease. Early secondary graft patency (0 to 30 days) was 92% for the in vitro endothelial cell lining group and 53% for control patients. The amputation rate after 18 months for the in vitro endothelial cell lining group was 15%, with a 31% rate in the control group. The functional performance of the in vitro endothelial cell lining bypasses was superior to that of untreated bypass grafts during the observed follow-up period. These early results suggest that in vitro endothelial cell lining is a method that can reduce the early occlusion rate now seen after repeat reconstruction of crural vessels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538510

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants.

Authors:  Hardean E Achneck; Ryan M Jamiolkowski; Alexandra E Jantzen; Justin M Haseltine; Whitney O Lane; Jessica K Huang; Lauren J Galinat; Michael J Serpe; Fu-Hsiung Lin; Madison Li; Amar Parikh; Liqiao Ma; Tao Chen; Bantayehu Sileshi; Carmelo A Milano; Charles S Wallace; Thomas V Stabler; Jason D Allen; George A Truskey; Jeffrey H Lawson
Journal:  Biomaterials       Date:  2010-11-05       Impact factor: 12.479

Review 2.  Engineering of bypass conduits to improve patency.

Authors:  S T Rashid; H J Salacinski; B J Fuller; G Hamilton; A M Seifalian
Journal:  Cell Prolif       Date:  2004-10       Impact factor: 6.831

3.  The cell and molecular biological approach to biomaterial research: a perspective.

Authors:  C J Kirkpatrick; M Wagner; H Köhler; F Bittinger; M Otto; C L Klein
Journal:  J Mater Sci Mater Med       Date:  1997-03       Impact factor: 3.896

Review 4.  Indications for routine heart-catheterization after CABG and PTCA.

Authors:  A Breeman; P W Serruys
Journal:  Int J Card Imaging       Date:  1993

5.  Point-of-Care Rapid-Seeding Ventricular Assist Device with Blood-Derived Endothelial Cells to Create a Living Antithrombotic Coating.

Authors:  Maria Noviani; Ryan M Jamiolkowski; Justin E Grenet; Qiuyu Lin; Tim A Carlon; Le Qi; Alexandra E Jantzen; Carmelo A Milano; George A Truskey; Hardean E Achneck
Journal:  ASAIO J       Date:  2016 Jul-Aug       Impact factor: 2.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.